Platelet-Rich Plasma Injection Versus Hydrodissection in the Treatment of Carpal Tunnel Syndrome

Launched by OSAMA AHMED ELSHAFEI · Apr 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for Carpal Tunnel Syndrome, a condition that causes pain and numbness in the hand due to pressure on a nerve in the wrist. The researchers want to find out which treatment is more effective: an injection of Platelet-Rich Plasma (a substance made from your own blood that may help healing) or Hydrodissection (a method that uses a mix of saline, a steroid, and a numbing medicine to ease symptoms). They will also look at how safe each treatment is for patients.

To participate in this trial, you need to be between the ages of 18 and 75 and have been diagnosed with Carpal Tunnel Syndrome for at least three months. You cannot have had certain previous treatments or have specific other nerve conditions. If you join, you will be randomly assigned to receive one of the two treatments and will return to the clinic for follow-up visits one and three months later to see how well the treatment worked and check for any side effects. This trial is currently recruiting participants, and both men and women are welcome to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed clinically as carpal tunnel syndrome with at least 3 months of symptoms and confirmed electro-physiologically as carpal tunnel syndrome
• Exclusion Criteria:
• • Onset of carpal tunnel syndrome during pregnancy
• • Co-existence of brachial plexopathy or thoracic outlet syndrome by clinical examination
• • Previous carpal tunnel decompressive surgery or corticosteroid injection in carpal tunnel
• • Patients with infection or local edema at the site of injection.